Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Parkinson Disease
Interventions: Biological/Vaccine: Allogeneic HB-adMSCs, Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: AZD6765 iv, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Chino, California • Lond Beach, California • San Diego, California + 30 more

Conditions: Crohn Disease (CD)
Interventions: DB-3Q, Placebo; Biological · Other
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: Hylenex, Normal Saline; Drug
Lead sponsor: Tissa Hata, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Familial Hypoalphalipoproteinemia
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: Placebo, GLSI-100; Biological
Lead sponsor: Greenwich LifeSciences, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 51
States / cities: Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more

Conditions: Fasciitis, Plantar
Interventions: Micronized dHACM, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Carlsbad, California • Carmichael, California + 14 more

Conditions: Hepatitis C
Interventions: Placebo, TG4040; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 2
States / cities: St Louis, Missouri • Cincinnati, Ohio

Conditions: Status Asthmaticus
Interventions: Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg; Drug
Lead sponsor: GemVax & Kael; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more

Conditions: Mammoplasty, Postoperative Pain
Interventions: Instillation - EXPAREL, Infiltration - EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Papulopustular Rosacea
Interventions: Cromolyn Sodium, Normal Saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Fever, Critical Illness
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions: Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: COVID-HIGIV, Placebo (saline); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Equinus Contracture
Interventions: Botulinum toxin type A, sodium chloride; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions: OnabotulinumtoxinA 100 UNT; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Tampa, Florida

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Osteoarthritis, Degenerative Joint Disease
Interventions: Bupivicaine + epinephrine, Bupivacaine, Ropivacaine, Ketorolac, Clonidine Injection; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: N6022, Normal saline; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more

Search by objective public record fields.

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Effects of Botox in Obstructed Defecation Syndrome

Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

TG4040 in Patients With Chronic HCV

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Study of EXPAREL in Patients Undergoing Breast Augmentation

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation